v3.25.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Jun. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 2,758.8 $ 2,375.0
Inventory 2,274.3 2,460.5
Other current assets 850.6 752.5
Total current assets 7,967.7 7,456.8
Property, plant and equipment, net 3,098.8 3,181.3
Operating lease assets 334.5 356.4
Intangible assets, net 9,467.5 9,691.2
Goodwill 6,493.1 6,478.9
Deferred tax asset 330.9 324.2
Investments and other assets 637.7 560.5
Total assets 28,330.2 28,049.3
Current liabilities:    
Current portion of notes payable 0.0 1,748.6
Taxes payable 114.8 548.3
Accounts payable 408.4 424.2
Accrued expense and other 2,660.5 2,807.7
Total current liabilities 3,183.7 5,528.8
Notes payable 6,283.7 4,547.2
Deferred tax liability 118.3 190.5
Long-term operating lease liabilities 310.9 334.5
Other long-term liabilities 799.6 732.3
Total liabilities 10,696.2 11,333.3
Commitments, contingencies and guarantees
Biogen Inc. shareholders’ equity:    
Preferred stock, par value $0.001 per share 0.0 0.0
Common stock, par value $0.0005 per share 0.1 0.1
Additional paid-in capital 714.0 569.4
Accumulated other comprehensive income (loss) (238.1) (136.2)
Retained earnings 20,135.1 19,259.8
Treasury stock, at cost (2,977.1) (2,977.1)
Total equity 17,634.0 16,716.0
Total liabilities and equity 28,330.2 28,049.3
Nonrelated Party    
Current assets:    
Accounts receivable, net of allowance for doubtful accounts of $2.9 and $2.2, respectively 1,624.2 1,404.8
Related Party    
Current assets:    
Accounts receivable, net of allowance for doubtful accounts of $2.9 and $2.2, respectively $ 459.8 $ 464.0